Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
247.6 EUR | +0.81% | -.--% | -.--% |
05-30 | ROCHE HOLDINGS AG : Goldman Sachs remains a Sell rating | ZD |
05-29 | Swiss Stocks Fall as Rate Jitters Intensify Amid Latest Inflation Data | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's enterprise value to sales, at 3.26 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 203B | - | ||
+39.82% | 731B | C+ | ||
+31.34% | 586B | B | ||
-7.31% | 348B | C+ | ||
+14.23% | 319B | B- | ||
+0.86% | 273B | C+ | ||
+13.47% | 235B | B+ | ||
+7.49% | 202B | B- | ||
+4.51% | 159B | C+ | ||
-2.05% | 158B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- RHO Stock
- Ratings Roche Holding AG